Tasipimidine and cyp2d6 inhibitor combination treatment
AssigneeOrion Corporation
InventorsMarja KÄHKÖNEN, Juha ROURU, Päivi TAAVITSAINEN, Johanna TUUNAINEN
Life of this patent
Estimating the term…
Abstract
The invention relates to co-administration of a CYP2D6 inhibitor with tasipimidine, or a pharmaceutically acceptable salt thereof, in order to improve the pharmacokinetic profile of tasipimidine by decreasing its clearance and inter-individual variation. The invention also relates to a combination of tasipimidine, or a pharmaceutically acceptable salt thereof, and a CYP2D6 inhibitor, and the use of such a combination for the treatment of a disorder, condition or disease where an alpha2A agonist is indicated to be useful, for example, for use in the treatment of neuropsychiatric disorders.
Claims17
A combination comprising tasipimidine, or a pharmaceutically acceptable salt thereof, and a CYP2D6 inhibitor.
2-4. (canceled)
8-9. (canceled)
A method of administering tasipimidine, wherein the method comprises administering tasipimidine or a pharmaceutically acceptable salt thereof, in combination with a CYP2D6 inhibitor, to a human being in need of treatment with tasipimidine.
A method for the treatment of a neuropsychiatric disorder, wherein the method comprises administering a therapeutically effective amount of tasipimidine or a pharmaceutically acceptable salt thereof, in combination with a CYP2D6 inhibitor, to a human being in need of treatment with tasipimidine.
Dependencies are inferred from the claim text.